News Sentiment

INBX sentiment intelligence

Inhibrx Biosciences, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 87.39 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-6.0% over one week, -6.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX)

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -6.0% Price reacting lower
Trend fit Trend active -6.1% over four weeks
Fair value 115.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 30
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 7
TradingView 6
PR Newswire 3
Stock Traders Daily 3
simplywall.st 3
www.marketscreener.com 3
Sahm 3

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 12
Balance sheet 4
Regulatory and legal 4
Analyst action 3
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Bitget Direct company coverage

Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million

Inhibrx Biosciences has expanded its loan facility with Oxford Finance to $500 million through a second amendment to their agreement. This expansion includes a new tranche of up to $325 million, with $100 million funded immediately as a Term C Loan and an additional $225 million

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 08:39
Source
Bitget
TradingView Direct company coverage

Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants

Inhibrx Biosciences expanded its senior secured credit facility with Oxford Finance and other lenders to up to $500 million, immediately drawing $100 million. The company also issued warrants for 21,457 shares to the lenders and pledged its equity in Poplar Therapeutics as collat

Tone
Positive 71/100
Event
Balance sheet
Published
16 Jul 2026 20:11
Source
TradingView
Stock Titan Direct company coverage

Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit

Inhibrx Biosciences has significantly expanded its credit facility with Oxford Finance to an aggregate principal amount of up to $500 million, including an immediate $100 million Term C Loan and potential additional Term D Loans of $225 million. This expansion is outlined in an 8

Tone
Positive 64/100
Event
Balance sheet
Published
16 Jul 2026 20:11
Source
Stock Titan
Moomoo Direct company coverage

Press Release: Inhibrx Announces Amended Loan Agreement With Oxford Finance, Expanding Total Facility to $500.0 Million

Inhibrx has announced an amended loan agreement with Oxford Finance, increasing its total debt facility from $200.0 million to $500.0 million. This expanded financing is expected to provide greater financial flexibility as Inhibrx approaches potential commercialization for its dr

Tone
Positive 74/100
Event
Balance sheet
Published
16 Jul 2026 19:10
Source
Moomoo
Stock Traders Daily Direct company coverage

Price-Driven Insight from (INBX) for Rule-Based Strategy

Inhibrx Biosciences Inc (NASDAQ: INBX) is showing strong sentiment across all horizons, supporting an overweight bias. AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysi

Tone
Positive 81/100
Event
Market update
Published
12 Jul 2026 16:58
Source
Stock Traders Daily
Benzinga España Direct company coverage

Inhibrx Biosciences (INBX) Stock Analysis Report | Financials & Insights

This report provides a stock analysis for Inhibrx Biosciences (INBX), a clinical-stage biopharmaceutical company. It details the company's general information, current stock performance, and a methodology for grading the stock based on various financial metrics. The analysis high

Tone
Positive 69/100
Event
Market update
Published
07 Jul 2026 06:11
Source
Benzinga España
Simply Wall Street Direct company coverage

How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors

Inhibrx Biosciences (INBX) was reclassified from Russell value/defensive indices to growth/small-cap indices in late June 2026. This shift primarily affects the type of investors holding the stock and doesn't change the underlying business catalysts, which include regulatory prog

Tone
Neutral 50/100
Event
Regulatory and legal
Published
03 Jul 2026 02:40
Source
Simply Wall Street
Stock Traders Daily Direct company coverage

(INBX) Price Dynamics and Execution-Aware Positioning

This article analyzes Inhibrx Biosciences Inc (NASDAQ: INBX) price dynamics, identifying a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional 97.2:1 risk-reward setup, targeting a substantial gain with minimal risk. The analysis provides t

Tone
Positive 64/100
Event
Market update
Published
01 Jul 2026 15:40
Source
Stock Traders Daily
www.marketscreener.com Direct company coverage

Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index

Inhibrx Biosciences, Inc. (NasdaqGS: INBX) has been removed from the Russell 2000 Defensive Index. This change is part of broader index adjustments, as the company was also added to other Russell indices like the Russell 2500 Growth and Russell 2000 Growth Benchmarks around the s

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 21:12
Source
www.marketscreener.com
Sahm Direct company coverage

Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In?

Inhibrx Biosciences (INBX) received FDA acceptance for its Biologics License Application for ozekibart, following positive Phase III data. Despite significant past share price momentum and an analyst target considerably higher than the current trading price, the company's financi

Tone
Neutral 50/100
Event
Analyst action
Published
29 Jun 2026 13:12
Source
Sahm
www.marketscreener.com Direct company coverage

Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark

Inhibrx Biosciences, Inc. (NasdaqGS: INBX) has been added to the Russell 3000E Growth Benchmark. This pharmaceutical company, which specializes in developing novel biologic therapeutic candidates, is actively advancing its clinical pipeline, including therapies like ozekibart (IN

Tone
Positive 81/100
Event
Market update
Published
29 Jun 2026 08:41
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Inhibrx Biosciences, Inc.(NasdaqGS:INBX) dropped from Russell 2000 Value-Defensive Index

Inhibrx Biosciences, Inc. (NasdaqGS:INBX) has been removed from the Russell 2000 Value-Defensive Index. This change is part of broader Russell index reconfigurations, which also saw the company dropped from other defensive/value benchmarks and added to growth benchmarks like the

Tone
Negative 38/100
Event
Market update
Published
29 Jun 2026 03:09
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to revenue forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX

This article provides a financial snippet for Inhibrx Biosciences, Inc. (NASDAQ: INBX), focusing on its enterprise value to revenue forward metric. It details that the market is currently closed with no trades recorded for the company. The content appears to be a stub or a brief

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 18:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX

This article provides financial data, specifically the "Price to sales forward" for Inhibrx Biosciences, Inc. (NASDAQ: INBX). It notes that the market is closed with no trades recorded at the time of publication and lists the company on the Nasdaq Stock Market. The content is pri

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 06:39
Source
TradingView
MarketBeat Direct company coverage

Inhibrx Biosciences (INBX) Short Interest & Short Float | Updated Jun 2026

Inhibrx Biosciences (INBX) reported a short interest of 3.30 million shares as of June 15, 2026, representing 27.52% of its public float, an increase of 3.79% from the previous report. The short interest ratio is 10.3 days to cover, indicating significant pessimism towards the st

Tone
Negative 37/100
Event
Market update
Published
26 Jun 2026 00:10
Source
MarketBeat
TradingView Direct company coverage

INBX Forecast — Price Target — Prediction for 2027

This article provides a forecast for Inhibrx Biosciences, Inc. (INBX) stock, including analyst price targets, past performance, and basic financial information. It notes that analysts have a maximum estimate of $325.00 and a minimum estimate of $230.00 for INBX's future price. Th

Tone
Positive 61/100
Event
Analyst action
Published
25 Jun 2026 15:10
Source
TradingView
Simply Wall Street Direct company coverage

The Bull Case For Inhibrx Biosciences (INBX) Could Change Following FDA BLA Acceptance For Ozekibart

Inhibrx Biosciences' investment narrative is shifting due to the FDA's acceptance of its Biologics License Application (BLA) for ozekibart to treat conventional chondrosarcoma. This approval sets a PDUFA decision date for April 14, 2027, converting a development-stage asset into

Tone
Positive 65/100
Event
Regulatory and legal
Published
23 Jun 2026 20:10
Source
Simply Wall Street
Stock Traders Daily Direct company coverage

(INBX) as a Liquidity Pulse for Institutional Tactics

This article analyzes Inhibrx Biosciences Inc (NASDAQ: INBX) using AI models to provide institutional trading strategies. Key findings indicate a positive near-term sentiment but a weak mid-term bias within a long-term strong context, with an exceptional 97.9:1 risk-reward setup.

Tone
Positive 77/100
Event
Balance sheet
Published
20 Jun 2026 14:40
Source
Stock Traders Daily
Sahm Direct company coverage

Inhibrx Biosciences (INBX) Stock Near Analyst Target After FDA Filing for Ozekibart

Inhibrx Biosciences (INBX) is gaining attention after the FDA accepted its Biologics License Application for ozekibart, used in treating chondrosarcoma, supported by positive trial data. While the stock has seen a significant one-year return, its 30-day performance shows a recent

Tone
Positive 62/100
Event
Analyst action
Published
19 Jun 2026 23:09
Source
Sahm
Bitget Direct company coverage

What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history

Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical company specializing in novel biologic therapeutics for life-threatening conditions, particularly oncology and rare diseases, using its proprietary single-domain antibody (sdAb) platform. Following a spin-off

Tone
Positive 75/100
Event
Market update
Published
19 Jun 2026 20:40
Source
Bitget
TradingKey Direct company coverage

Inhibrx Biosciences Inc (INBX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Inhibrx Biosciences Inc (INBX)'s dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and reports "No Data" for both historical dividend dates and stock splits. The piece highl

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 09:09
Source
TradingKey
Investing.com South Africa Direct company coverage

Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com

Inhibrx Biosciences Inc. (NASDAQ:INBX) shares rose 2.6% after the FDA accepted its drug application for ozekibart, a treatment for unresectable or metastatic conventional chondrosarcoma. The FDA set an April 14, 2027 goal date, with ozekibart poised to be the first FDA-approved t

Tone
Positive 90/100
Event
Market update
Published
16 Jun 2026 07:40
Source
Investing.com South Africa